This trial will test a new treatment for people with inactive chronic hepatitis B who have low levels of hepatitis B surface antigen. The treatment will be evaluated for its ability to fight the virus, its safety, and its ability to provoke an immune response.
1 Primary · 2 Secondary · Reporting Duration: Baseline to Day 169
Experimental Treatment
Non-Treatment Group
80 Total Participants · 2 Treatment Groups
Primary Treatment: HepTcell · Has Placebo Group · Phase 2
Age 18 - 65 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:| California | 100.0% |
| 65+ | 33.3% |
| 18 - 65 | 66.7% |
| Stanford University Department of Medicine | 66.7% |
| Toronto Liver Centre | 33.3% |
| Met criteria | 100.0% |